PMID- 37426135 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20230718 IS - 2072-1439 (Print) IS - 2077-6624 (Electronic) IS - 2072-1439 (Linking) VI - 15 IP - 6 DP - 2023 Jun 30 TI - Effective omalizumab treatment influenced eosinophil function in severe allergic asthmatics. PG - 3115-3125 LID - 10.21037/jtd-22-1818 [doi] AB - BACKGROUND: Omalizumab is an effective anti-immunoglobulin E (IgE) treatment for allergic asthma. Eosinophil plays a critical role in the pathogenesis of allergic airway inflammation. This study aimed to explore the influence of effective omalizumab treatment on circulating eosinophils. METHODS: Allergic asthmatics enrolled in the study were treated with omalizumab for at least 16 weeks and exhibited a good or excellent response according to the global evaluation of treatment effectiveness (GETE) assessed by each patient and specialist physician. For eosinophil functional evaluation, peripheral blood eosinophils were separated; and examined the expression of human leukocyte antigen (HLA)-DR and co-stimulatory molecules cluster of differentiation (CD) 80, CD86 and CD40 by Flow Cytometry and serum were to measure the concentration of eotaxin-1 before and after 16 weeks of omalizumab treatment. RESULTS: Totally 32 allergic asthma patients who responded positively to omalizumab treatment were included. Omalizumab responders showed a significant decline in the expression of co-stimulatory molecules CD40, CD80, and CD86 on peripheral eosinophils and in serum eotaxin-1 concentration after treatment. Negative correlations (r=-0.61, P=0.048) were observed between the change in CD80(+) eosinophils and the change in forced expiratory volume in the first second (FEV1)/forced vital capacity (FVC)% predicted and maximal expiratory flow (MEF) 25% after omalizumab treatment. Omalizumab improved FEV1/FVC% predicted (3.88, P=0.033), fractional exhaled nitric oxide (FeNO, -22.24, P=0.028), asthma control test (ACT, 4.22, P<0.001), mini asthma quality of life questionnaire (mini-AQLQ, -14.44, P=0.019), Leicester cough questionnaire (LCQ, 3.03, P=0.009) and visual analogue scale (VAS) for allergic symptoms (-13.00, P=0.001) in patients with severe allergic asthma statistically; reduced mini rhino-conjunctivitis quality of life questionnaire (mini-RQLQ, -8.50, P=0.047), and self-rating anxiety scale (SAS, -5.08, P=0.040) in allergic asthmatics with concomitant allergic rhinitis (AR) or anxiety, respectively. CONCLUSIONS: Our findings show a unique role of omalizumab in reducing co-stimulatory molecules expression on eosinophil and serum eotaxin-1 levels in severe allergic asthmatics accompanied by improvement of multiple clinical parameters of allergic diseases. CI - 2023 Journal of Thoracic Disease. All rights reserved. FAU - Yan, Huacheng AU - Yan H AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Sun, Lin AU - Sun L AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Ni, Yingmeng AU - Ni Y AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Du, Juan AU - Du J AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Liu, Dong AU - Liu D AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Wang, Ping AU - Wang P AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Cao, Jin AU - Cao J AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Xu, Guofang AU - Xu G AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Tao, Yi AU - Tao Y AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. FAU - Dai, Ranran AU - Dai R AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. FAU - Tang, Wei AU - Tang W AD - Department of Pulmonary and Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Institute of Respiratory Diseases, Shanghai Jiao Tong University School of Medicine, Shanghai, China. AD - Shanghai Key Laboratory of Emergency Prevention, Diagnosis and Treatment of Respiratory Infectious Diseases, Shanghai, China. LA - eng PT - Journal Article DEP - 20230522 PL - China TA - J Thorac Dis JT - Journal of thoracic disease JID - 101533916 PMC - PMC10323569 OTO - NOTNLM OT - Allergic asthma OT - co-stimulatory molecules OT - eosinophil OT - omalizumab COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://jtd.amegroups.com/article/view/10.21037/jtd-22-1818/coif). The authors have no conflicts of interest to declare. EDAT- 2023/07/10 06:42 MHDA- 2023/07/10 06:43 PMCR- 2023/06/30 CRDT- 2023/07/10 05:06 PHST- 2022/12/16 00:00 [received] PHST- 2023/04/21 00:00 [accepted] PHST- 2023/07/10 06:43 [medline] PHST- 2023/07/10 06:42 [pubmed] PHST- 2023/07/10 05:06 [entrez] PHST- 2023/06/30 00:00 [pmc-release] AID - jtd-15-06-3115 [pii] AID - 10.21037/jtd-22-1818 [doi] PST - ppublish SO - J Thorac Dis. 2023 Jun 30;15(6):3115-3125. doi: 10.21037/jtd-22-1818. Epub 2023 May 22.